Please assess the completion status of the following clinical trial:

Trial Title: The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 16 years of age or older.~* Patients who were diagnosed as moderate to severe community acquired pneumonia requiring initial intravenous therapy and hospitalization.~Exclusion Criteria:~* Known or suspected hypersensitivity or intolerance to ampicillin sodium/sulbactam sodium, other penicillins, or cephems.~* Hepatic dysfunction \[Aspartate Aminotransferase(AST), Alanine Aminotransferase (ALT), total bilirubin \> 3 times upper limit of normal range values\].~* Severe renal dysfunction (creatinine clearance \< 30 ml/min).~* Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- ampicillin sodium/sulbactam sodium (Type: EXPERIMENTAL): ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV

Based on this trial design, predict the completion outcome and termination type (if applicable).